Kainate Receptor Antagonists to Treat Neuropathis Pain

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$744,554.00
Award Year:
1998
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Agency Tracking Number:
39570
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Bearsden Bio, Inc.
600 Swedesford Rd, Frazer, PA, 19104
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
STURGESS, MICHAEL A
() -
Business Contact:
(215) 386-7630
Research Institution:
n/a
Abstract
The development of novel compounds that regulate specific subtypes of glutamate receptors for the treatment of CNS disorders is the major goal of Symphony Pharmaceuticals, Inc. Symphony discovered a novel series of heterocyclic 1,2-dihydrophthalazines that selectively antagonize AMPA receptors and protect animals in seizure models. Our hypothesis is that a 1 ,2-dihydrophthalazine AMPA receptor antagonist would be a safe and clinically useful drug for the treatment of seizure disorders such as epilepsy. Phase I specific aims are to: 1) Synthesize the individual stereo isomers of SYM 2206 and two non-chiral-center containing analogs of SYM 2206. 2) Test each new analog for its ability to protect mice and rats against seizures at non-toxic doses. 3) Select a compound for preclinical toxicology and pharmacokinetic evaluation in Phase II of the proposal. The work in Phase Il is expected to complete the preclinical development of one of the compounds. Phase III will comprise clinical trials for the treatment of epilepsy or other seizure disorders.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government